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Abstract 
This review paper discusses the process of disc degeneration and the current 
understanding of cellular degradation in patients who present with low back pain.  
The role of surgical treatment for low back pain is analysed with emphasis on the 
proven value of spinal fusion. The interesting and novel developments of stem cell 
research in the treatment of low back pain are presented with special emphasis on 
the importance of the cartilaginous end plate and the role of IL-1 in future treatment 
modalities. 
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Introduction; 
Low back pain (LBP) affects many people posing a major public health problem 
worldwide1 and in the United States back and neck pain are two of the most common 
reasons for visiting primary health care physicians and chiropractors2. Hoy et 
al.,(2010) concluded that LBP caused more global disability than any other condition 
and with an aging population stressed the importance for further research to gain a 
greater understanding into the causes of this problem3. LBP can present clinically as 
acute that is less than six weeks, sub-acute six to twelve weeks and chronic more 
than 12 weeks4. Many patients with chronic LBP have periods free from pain, 
followed by episodes of increasing pain and disability and can be further classified as 
suffering from chronic recurrent LBP. The causes of LBP are mostly unknown, 
however degeneration of the intervertebral disc (IVD) is believed to precede the 
clinical presentation which includes LBP and or lower limb pain along with 
paraesthesia, spinal stenosis and disc herniation5. Several factors have been 
suggested as being primary risk factors for LBP, including mechanical loading, age, 
obesity and smoking6-9. Genetics has been shown to have a major role in the 
development of disc degeneration10-12 and recently the involvement of bacteria has 
been revisited to raise the possibility of bacterial infection as a cause of disc 
degeneration13-15. Viruses have also been suggested as causing disc degeneration 
by Alpantaki et al(2011)who isolated the herpes simplex virus type 1 (HSV-1) 
together with cytomegalovirus from the IVD of patients who underwent spinal surgery 
for disc prolapse16.  
 
The Normal Intervertebral disc 
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The IVD is an avascular and aneural structure17,18, composed of three 
morphologically distinct regions, a hyaline cartilaginous layer which separates the 
IVD from the adjacent vertebrae known as the cartilaginous end plate (CEP) and a 
highly organised outer collagenous annulus fibrosus (AF) surrounding a more 
gelatinous nucleus pulposus (NP).There are a small number of metabolically active 
cells within the IVD which has been estimated as 9 x 106 cell/cm3 within the AF and 4 
x 106 cell/cm3 in the NP19. The nutrition of the disc is dependent on the transfer of 
solutes from the capillaries in the vertebral endplate and outer annulus fibrosus by 
the process of passive free diffusion dependent upon the Fick principle20-22. These 
vessels end in the CEP and are in continuity with the systemic circulation via the 
lumbar arteries23. Blood flow to the end plates of sheep has been estimated as 
4ml/100gm/min which is similar to the cortical blood flow in the tibia24. Wallace et al 
(1994) have shown that the blood flow can be influenced by neuro humeral agents 
such has acetyl choline, which doubles the blood flow to the IVD25. IVD cells are also 
capable of surviving with low levels of oxygen whilst levels of glucose area much 
more crucial factor with low glucose levels leading to premature cells death 
especially in an acidic environment26. In addition, the activity of IVD cells can be 
influenced by mechanical load with physiologically normal loading regimes 
considered to induce anabolic responses whilst abnormal loading induces catabolic 
responses27-34. 
Mechanically, the IVD is capable of withstanding pressure especially as the body 
moves when bending and twisting but there is no evidence that the IVD acts 
as'shockabsorber'27,35. Whilst excessive loading or abnormal loading such as 
vibration can induce damage in the form of end plate rupture and micro-fissure 
formation36.  
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The Pathology of Disc Degeneration; 
Yong-Hing and Kirkaldy-Willis(1983)and Boos et al(1994)studied the radiological and 
pathological changes that take place in the IVD and facet joints especially with 
advancing age37,38. Disc degeneration results in loss of disc height with subsequent 
altered mechanical stress on the facet joints and other spinal tissues, such as the 
ligamentum flavum which have been shown to undergo changes in patients with 
LBP39. Loss of disc height can also contribute further to compression of the exiting 
nerve root resulting in lower limb and leg and buttock pain and Olmarker and 
Rydevik (1992)demonstrated that long term compression on the exiting nerve root 
can lead to changes within the spinothalamic tract40.  
It has also been shown that LBP may be attributed to the ingrowth of nociceptive 
nerves and blood vessels into the inner regions of the IVD. Freemont et al., (1997) 
identified the presence of peptide-containing sensory nerve fibres within inner 
regions of the degenerate IVD, and found them to be localised to microvessels in 
patients experiencing pain41. It was later discovered that these microvessels 
expressed the neurotrophic factor: NGF (nerve growth factor) which is the main 
neurotrophin responsible for the survival and growth of neurons, and these nerve 
fibres expressed the high affinity receptor for NGF: Trk A42. This led to the 
hypothesis that blood vessels entered the degenerate IVD first, followed by nerves. 
The expression of neuropeptides such as Substance P, PECAM, CGRP and NT3 
further suggests that the nerves present within the IVD are able to actively transmit 
signals in response to painful stimuli, such as abnormal load42-45. There are various 
molecules present within the native IVD which contribute to the avascular and 
aneural nature of this tissue. Aggrecan (the major proteoglycan) is found in 
abundance within the healthy NP and provides hydration via its ability to imbibe 
water19. In vitro studies demonstrated that aggrecan isolated from the native IVD was 
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able to inhibit the growth and migration of nerves and blood vessels46. Other 
endogenous molecules within the IVD have been studied for their inhibitory 
properties towards nerve and blood vessel ingrowth such as chondromodulin47,48 and 
tissue inhibitors of metalloproteinase-1 (TIMP-1) and TIMP-249,50. More recently, the 
semaphorins have been implicated in having a role in the prevention of innervation 
and angiogenesis of the IVD51 and articular cartilage52. During IVD degeneration 
however, such molecules are known to become depleted and thus could lead to the 
inappropriate entry of nerves and blood vessels into the vulnerable degenerate IVD. 
These potential regulators of nerve and blood vessel ingrowth into the IVD have 
recently been reviewed by Binch et al., (2014). The question still remains as to what 
may trigger the cascade of events leading to the innervation and vascularisation of 
the IVD53. Recent studies by Binch et al., (2014) and Krock et al., (2014) confirmed 
expression of a variety of neurotrophins from NP cells and IVD organ cultures 
respectively45,54, and concluded that levels of brain derived neurotropic factor 
(BNDF)particularly were significantly higher in degenerate IVD samples as opposed 
to non-degenerate samples.  
IVD degeneration is characterised by a number of discrete biochemical, histological, 
metabolic and functional changes, Figure 1, leading to changes in the extracellular 
matrix composition resulting in dehydration which consequently alters the response 
to compressive loads55. The changes within the disc result from abnormal cell 
behaviour thought to be brought about by abnormal mechanical loading30,56, altered 
nutritional supply57-59 and genetic predisposition60-63. As degeneration progresses the 
extracellular matrix composition within the NP changes becoming progressively more 
fibrous with reduced proteoglycan synthesis and increased degradation of the matrix 
by degradative enzymes44,64. Two main families of degradative enzymes are 
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involved in the degradation of the matrix during IVD degeneration, these being the 
matrix metalloproteinases (MMPs) and A disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTs) enzymes65-69. Both these groups of enzymes are 
produced particularly by the NP cells of degenerate discs and have been shown to 
lead to the degradation of collagens and proteoglycans within the degenerate disc 
65,68,70. These compositional changes in the matrix during IVD degeneration are 
driven by biochemical changes to the cells. In addition to increased cellular 
apoptosis71-73 and senescence74-76 seen during degeneration. The cells of the IVD 
produce a plethora of catabolic cytokines and chemokines77-87 with highest 
expression seen in the NP and inner AF77,80, expression within the outer AF is 
differentially expressed, with posterior AF tissue displaying higher expression of 
cytokines than the anterior AF85.  
 
There is increasing evidence supporting the role of a pivotal cytokine: interleukin (IL)-
1 in the pathogenesis of IVD degeneration45,70,77,78,80,84,88-91. With an increase in the 
production of the IL-1 agonists (IL-1α and IL-1β) and their active receptor IL-1RI, 
without a concordant increase in the natural inhibitors: IL-1 receptor antagonist (IL-
1Ra) or the decoy receptor: IL-1RII; within the cells of the NP and inner AF80. IL-1 
has been shown to induce a plethora of catabolic events, which are linked to 
degradation of matrix70,80, neuronal ingrowth and blood vessel ingrowth into the 
normally aneural and avascular disc45,54,90,92. Inhibition of IL-1 in IVD tissue in vitro 
has been shown to completely abrogate matrix degradation70 whilst inhibition of TNF 
alpha had no such effect70. IL-1 has also been linked to induction of senescence in 
articular chondrocytes93, 94, and fibroblasts95 all of which are features associated with 
IVD degeneration Figure 1. The importance of IL-1 in the pathogenesis of disc 
degeneration was furthered by the observation that spontaneous IVD degeneration 
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occurred in a knockout mouse model where the natural inhibitor of IL-1 (IL-1Ra) was 
removed91, which is further supported by the findings that polymorphisms in the IL-1 
gene cluster increases the risk of IVD degeneration and LBP96-101. This improved 
understanding of the pathogenesis of disc degeneration holds potential to inhibiting 
further degeneration and creating the correct tissue niche for regenerative 
approaches. 
 
New Methods for assessing the Lumbar spine; 
Although MRI is now used widely for investigating and producing a qualitative image 
of a patients lumbar spine, new techniques have been developed such as 
quantitative MRI102 which allows for measurement of solutes across the IVD over 
time and also for dynamic MRI using two magnetic coils so that spinal function can 
be evaluated103. Another technique attracting interest is the use of laser Doppler to 
image the vascular supply to the IVD104. These newer quantitative techniques have 
real potential for measuring changes that occur in patients with LBP. 
 
Surgical treatment 
In the beginning of the 20th century the spine was usually operated on for 
tuberculosis. The method was spinal decompression and posterior spinal fusion as 
described by Albee (1911)105, Hibbs (1912)106 and Girdlestone (1923)107. 
 
Anterior approach; 
In the early part of the 20th century the anterior approach for treating patients with 
tuberculosis of the spine was considered by many surgeons to be too hazardous. In 
1906 Muller reported on his experience of the transabdominal access to the spine in 
patients with tuberculosis108. Muller concluded that the transabdominal approach 
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may seem too daring, but was surprised and satisfied with the relatively ease of 
access and visualisation achieved by this approach108. In 1933 Burns used the 
transabdominal approach on a boy aged 14 years and drilled a hole almost vertically 
downwards from L5 to the sacrum and inserted a cortical bone graft taken from the 
patient’s tibia109. This approach was the first recorded operation of exposing the 
lumbar spine by the transabdominal approach for a patient with LBP. In 1934 Ito et 
al., described an operation for the treatment of Pott’s disease of the spine and also 
used an anterior midline approach but proceeded by a retroperitoneal approach to 
arrive at the lumbar vertebrae110. In one of the ten patients, a bone graft from the 
tibia was inserted into the defect at the lumbosacral level110. In 1936 Mercer 
described the transabdominal approach for treating two patients with lumbar 
spondylolisthesis using an lilac crest bone graft with unfortunately a fifty percent 
mortality111. Over the next few decades the anterior transabdominal approach to the 
spine was used mainly for the treatment of tuberculosis of the spine. Hodgson and 
Stock (1956), showed that the spine could be exposed by the anterior route without 
causing major problems to the patient112, especially using the retroperitoneal 
approach, which gave confidence to surgeons in the anterior exposure of the lumbar 
spine. Figure 2. Cloward(1963) pioneered the interbody dowel technique113 which 
Crock developed further using the retroperitoneal approach to the lumbar spine23. 
 
Posterior approach; 
The posterior approach to the lumbar spine for patients with LBP was championed 
by Wiltse (1968) who developed the posterolateral fusion technique114 widely used 
today. Pedicular screw insertion has enabled rigid fixation to be achieved and 
enhanced the process of fusion. Figure 3. Although the technique of screw insertion 
needs to be precise and different approaches to screw insertion can lead to different 
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levels of security of fixation115. Equally so the posterior approach may lead to 
extensive muscle retraction which can cause posterior muscle necrosis116. It is also 
possible that fusion of the lumbar spine could also lead to an increase in the level of 
degeneration in the adjacent lumbar discs. Mannion et al (2014) undertook a long 
term study on patients who underwent lumbar spinal fusion and concluded that 
fusion was associated with loss of lower disc space height at the adjacent segment, 
which occurred on average at 13 years117. However they noted that in their study 
that the spinal fusion had no effect on patient self-rated outcomes. Partly to address 
this problem dynamic fixation using a posterior dynamic stabilisation technique was 
developed. Figure 4. Zhou et al 2013 undertook a systemic review of the literature 
on dynamic fixation and concluded that posterior dynamic stabilisation did protect the 
lumbar discs against adjacent segment degeneration118. 
Currently a combination of anterior and posterior fusion is now the standard 
operation for patients with LBP, particularly spondylolisthesis119 and is combined with 
iliac crest bone graft supplemented by Bone Morphogenic Protein120. Strube et al 
(2012) compared the results of anterior/posterior lumbar fusion at a single level with 
anterior fusion alone and reported that an anterior lumbar fusion alone can lead to 
better clinical results then anterior posterior spinal fusion and they concluded that a 
standalone single level fusion was adequate121. 
 
Multidisciplinary rehabilitation 
An alternative to spinal fusion for LBP is an intensive back rehabilitation. Fairbank et 
al (2005) reported in a prospective study on the effective outcome of an intensive 
rehabilitation programme compared to spinal fusion and showed that there was no 
difference between two groups of patients as far as spinal function and patient 
satisfaction were concerned122. These same patients in this study were followed up 
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by Mannion who in 2013 reported that at 11 years there was no difference between 
the spinal fusion patients and those who underwent intensive rehabilitation123. 
Mannion et al concluded that the risks of surgery and the lack of deterioration of the 
non-operative patients ‘outcomes, over time, suggested that lumbar fusion in chronic 
LBP should not be favoured particularly when multidisciplinary cognitive behavioural 
and exercise rehabilitation programmes were available123. In distinction Wood et 
al(2011)concluded that for a patient with a clearly defined spondylolisthesis there 
seemed to be a benefit from spinal fusion and in a comprehensive review of the 
literature reasoned that spinal fusion should be considered for patients with an 
isthmic spondylolisthesis and also for patients who had failed non operative 
treatment124. 
 
Total Disc Replacement. 
Total disc replacement (TDR) is an alternative to spinal fusion with the advantage of 
restoring flexibility to the intervertebral joint. Most current designs of TDR are ball-
and-socket joints involving articulation of ultra-high molecular weight polyethylene on 
metal or metal-on-metal. Figure 5. The technology is based on total hip replacement 
to achieve a low friction joint. More recently, TDR prostheses have been 
manufactured from flexible polymeric materials to more closely mimic the natural 
disc35.  
The Norwegian multi centre RCT (2014) reported that TDR was cost effective when 
compared with multi-disciplinary rehabilitation125, but with only a two year follow up 
they stressed that their results needed to be treated with caution. A Cochrane review  
(2012) on the use of TDR in LBP however could not find any evidence of better 
outcomes in terms of LBP and patient function between those who had TDR and 
those who underwent spinal fusion and they also advised caution on adopting TDR 
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on a large scale126,127. However Siepe et al (2014) in a prospective study reporting 5 
to 10 year follow up concluded that TDR should be considered as a viable treatment 
alternative to lumbar fusion128. 
 
Other Surgical Techniques 
Other surgical techniques include minimally invasive techniques such as 
transforaminal lumbar interbody fusion, which were reviewed by Perez-Cruet et 
al(2014)in a prospective long meta-analysis and they noted that there was a 
significant clinical improvement in patients with LBP due to IVD degeneration and 
also in patients with spondylolisthesis129. These authors reported very low rates of 
failure of interbody fusions. Other techniques such as nucleus replacement, 
interspinous devices and minimally invasive intradiscal thermocoagulation are too 
new to know of their real outcomes and the evidence of their effectiveness is open to 
discussion130,131 
 
Future potential of Stem Cells 
Current proposed treatments, driven by clinical need and scientific research, have 
aimed to develop a biological therapeutic strategy which addresses the underlying 
pathogenesis of IVD degeneration. A vast amount of research has focused on the 
use of cells, either alone, or together with biomaterial scaffolds, in order to 
repopulate the NP and simultaneously regenerate the matrix. Cell therapy has been 
used for the repair of articular cartilage for over two decades132,133 but has only 
recently been applied to the IVD probably due to the challenges cell therapy faces in 
the IVD. The use of autologous NP cells would be the ideal strategy, however due to 
the low cellular abundance in the NP134, the harvesting of NP cells from more than 
one disc or in-vitro expansion of cells would be required to obtain a sufficient number 
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for transplantation. Furthermore autologous NP cells extracted from degenerate 
discs may be inappropriate for regenerative purposes due to the increased 
expression of catabolic factors135, decreased synthesis of normal matrix components 
and increased senescence displayed by these cells136, which could explain the 
limited regenerative potential of cells from herniated disc tissue in comparison to 
those from the non-herniated regions137. Concerns have also been raised regarding 
the needle puncture which is currently used to extract autologous NP cells, since this 
method has been shown to accelerate degenerative changes138,139,140. Other non-
autologous sources of cells have been investigated such as notochordal cells141-146, 
which are attractive as disc degeneration is less in animals, where they survive (such 
as in non-chondrodystrophoid dogs)147. Stem cells are an attractive cell source either 
from autologous or allogeneic sources since large numbers can be harvested from 
embryos or placenta/umbilical cords or adult tissues such as bone marrow and fat. 
Of these sources human mesenchymal stem cells (hMSC) are potentially the most 
attractive cell choice for IVD regeneration since they can be extracted from a variety 
of adult tissues148, they have proliferative capacity and thus can be easily cultured 
and expanded ex-vivo, they host the ability to differentiate into multiple cell 
lineages149 and finally they also avoid the ethical issues surrounding the use of 
embryonic stem cells. Recent studies have suggested that the source of MSCs are 
critical to the clinical outcome with improved expansive and chrondrogenic 
differentiation potential in synovial membrane and adipose tissue derived MSCs in 
comparison to bone marrow derived MSCs148,150. Increasing evidence has shown 
that hMSC are able to differentiate into NP like cells and produce a biologically 
functional NP matrix consisting of proteoglycans and collagen type II151-154. Studies 
have also shown that co-culture of hMSCs and NP cells not only enhances NP cell 
differentiation, but also restores normal cell function of degenerate NP cells, thus 
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aiding the repair process155,156. The use of stem cells alone for IVD repair has 
demonstrated some success, particularly in small animal models. Zhang et al., 
(2005) reported increased proteoglycan and collagen type II deposition from 
transplanted bone marrow derived MSCs in rabbit IVD154. Orozco et al., (2011) 
conducted a small human pilot study whereby ten patients with disc degeneration 
were injected with autologous bone marrow derived MSCs; following 12 months 
patients reported significant improvements in pain and disability and displayed 
increased water content in the NP, however disc height was not restored153. In 
contrast the transplantation of allogenic disc derived MSCs into denucleated lumbar 
discs in an in-vivo porcine model exhibited low cell survival and the formation of a 
collagen type I/II scar tissue following three months157.  
The success of hMSC used alone in IVD repair is varied, but may be improved by 
the use of an appropriate biomaterial scaffold which could provide additional 
mechanical support, facilitate cell survival, provide a scaffold for matrix deposition 
and possibly promote appropriate hMSC differentiation to an NP cell phenotype. In 
particular the use of thermo-reversible hydrogels which solidify at body temperature 
are an attractive choice for IVD repair since they provide a non-invasive cell delivery 
method for NP tissue regeneration158. The ideal load bearing, injectable biomaterial 
scaffold for IVD regeneration, which meets all requirements in terms of 
biocompatibility, bioactivity, mechanical properties and injectability, is yet to be 
produced, however increasing research into the development of hydrogels has 
produced a selection of scaffolds which have demonstrated success in terms of MSC 
regeneration of the NP. Richardson et al., (2008) cultured MSCs for 4 weeks seeded 
in a temperature-sensitive hydrogel chitosan–glycerophosphate (C/Gp) hydrogel and 
demonstrated differentiation of MSCs to an NP cell phenotype, with production of an 
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NP like matrix consisting of proteoglycans and collagens151. More recently Peroglio 
et al., (2013) investigated in-vitro and ex-vivo hMSC differentiation in a hyaluronan-
poly(N-isopropylacrylamide) (HA-pNIPAM) hydrogel under hypoxic conditions and 
reported successful discogenic differentiation with production of an NP like matrix159. 
The majority of studies have aimed to regenerate the NP since this is the main 
region which undergoes significant cellular and matrix changes during degeneration 
of the IVD135,160. Despite this, biological strategies which address the entire IVD may 
be required, particularly in severely degenerate cases where tears in the AF may 
result in extrusion of the implanted biomaterial and/or cells Figure 6. Consequently a 
variety of studies have investigated biphasic scaffolds which aim to repair the AF and 
NP simultaneously161-165. Lazenbnik et al., (2011) used a biomimetic strategy by 
combining porcine chondrocyte cell seeded agarose gel surrounded by cell seeded 
electrospun polycaprolactine fibres and observed that cells were viable, well 
distributed and orientated themselves in the direction of the fibres166. Furthermore 
the biphasic scaffolds were found to have higher moduli than agarose gels alone, 
thus providing enhanced mechanical properties which may be required to restore 
normal IVD biomechanics in severe stages of degeneration166. However in IVDs 
where endplate calcification has occurred which could result in decreased nutritional 
supply and poor cell survival tissue engineering a complete IVD with all three of its 
components (NP; AF; CEP) may be required167 Figure 6. Such a tissue engineered 
construct would compete with allogeneic disc transplants which have been 
pioneered by Ruan et al.,(2007), who implanted cadaveric cervical discs into patients 
with cervical IVD degeneration with encouraging clinical outcome and minimal loss of 
disc height at five year follow-up168. Despite increasing evidence demonstrating 
significant potential for MSC based regenerative strategies, there are still questions 
which remain to be answered, including: what is the ideal cell type and source? is 
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the use of a biomaterial scaffold necessary? at what stage of degeneration is 
regenerative cell therapy clinically applicable? Could cells be administered as part of 
an intervertebral ‘organ transplant’?35.  
Furthermore, assessing the regenerative capacity of MSCbased strategies to 
produce an appropriately biological functioning tissue is obstructed by a lack of 
understanding of the normal NP cell phenotype. The majority of studies, including 
those which have been discussed here, characterise NP cell differentiation using 
traditional chondrogenic genes such as aggrecan, collagen type II and sex 
determining region box 9(Sox-9)169,170. Despite this, cells and tissues of articular 
cartilage and NP demonstrate significant differences in terms of morphology, ECM 
deposition and biomechanical behaviour 171, thus elucidating a differential NP marker 
which can be used to inform and thoroughly assess MSC differentiation into 
biologically functioning NP cell is the current focus of many research 
studies172,173,174.  
Despite all the challenges and unknowns associated with cell therapy it has been 
used in the clinic in several centres. A clinical trial for treating herniated IVD following 
culture expansion of the resident cells reported a reduction in the patient’s pain level 
with no loss of disc height175,176. Autologous MSCs have also been used to treat 
patients, either within a collagen sponge implanted percutaneously177 or injected 
directly into the discs137. There remain, however, important issues to be addressed 
around cell based therapies for patients with discogenic LBP due to IVD 
degeneration. Central amongst which is whether a normal functioning CEP is 
required for treatment to be successful in order for IVD nutrition to be 
maintained178,179. Although recent data suggest that nutritional supply actually 
increases rather than decreases during disc degeneration57,180.   
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The Future  
At the moment posterior interbody spinal fusion for treating patients with LBP who 
have failed conservative treatment for at least 3 months or who are unable to 
respond to a multi-disciplinary rehabilitation programme is the best option for treating 
the pain and improving the patients overall function. Certainly in patients with an 
isthmic spondylolisthesis and probably with degenerative spondylolisthesis, surgical 
treatment after failed conservative treatment is the appropriate treatment. 
Noshchnenko et al (2014) in a systemic meta-analysis concluded that spinal fusion 
of the lumbar spine is an effective treatment for patients with severe chronic LBP 
181. However it is worth noting that the NHS commissioning Board for England 
recently stated that they would not commission spinal surgery for the treatment of 
chronic non-specific LBP 182. In the UK, total disc replacement has undergone a 
decline in use although it is interesting to note that sacroiliac joint fusion has risen, 
even though the long term results for this treatment are largely unknown183.  
It would seem therefore that the original operations devised primarily for treating 
tuberculosis, namely spinal fusion either anteriorly or posteriorly or combined, have 
contributed significantly to the management of patients with chronic LBP due to disc 
degeneration, especially those who have failed or are unable to complete a 
multidisciplinary rehabilitation programme. 
The future must, however, be to focus on alternative ways for treating chronic 
recurrent LBP which is where stem cell biotechnology may have the answers. Over 
the past two decades considerable research efforts have been focused on the 
development of biological strategies for IVD repair. In particular strategies to inhibit 
the pathogenesis of disc degeneration, particularly catabolic factors together with the 
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use of MSCs in combination with biomaterial scaffolds have shown significant 
promise in the regeneration of an NP like matrix and even a whole IVD. Despite this, 
there are still challenges emerging which must be overcome before such strategies 
can be incorporated into clinical practise.  Biomaterial research is critical to the 
continuing development of a bioactive and biocompatible material which has 
mechanical properties that replicates the natural disc and can be delivered via non-
invasive injection prior to in-situ solidification. Research to define the pathological 
state of degeneration as well as understanding the normal NP phenotype is also 
critical to ensure regeneration of the correct biologically functioning NP tissue. 
Furthermore the safety and efficacy of regenerative therapies must be thoroughly 
assessed in vivo in the degenerate disc microenvironment. Progress so far has 
shown future potential for the use of MSCs, either alone or in combination with 
monophasic or biphasic biomaterial scaffolds offering a selection of regenerative 
strategies that can be chosen depending on the stage of IVD degeneration, providing 
a less invasive and more efficacious alternative to surgery. If the possibilities outlined 
in this paper can be transferred to clinical practise and if the patient outcomes show 
real improvement then those treating patients with LBP due to disc degeneration will 
have come a long way from the seminal paper by Mixter and Barr in 1934184. 
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Figure Legends; 
 
Figure 1: Cellular and matrix components of the non-degenerate disc and their 
balance during normal homeostasis and the histological, biochemical, cellular 
changes which occur during degeneration.  
Figure 2: Radiograph of the lumbar spine showing 
a. cortico-cancellous bone graft as originally described by Mercer inserted 
between L4-5. 
b. Showing two cages inserted between the L4-5 and L5-S1 levels. 
 
Figure 3: Rigid fixation and bone graft in a patient with a degenerative L4-5 disc. 
 
Figure 4: A radiograph showing dynamic fixation of the L4-5 level. 
 
Figure 5: Radiographs showing a total disc replacement at the L3-4 level. 
 
Figure 6: Potential treatment strategies for disc degeneration are likely to be tailored 
to the stage of degeneration dependant on the tissues which require repair. Mild 
degeneration treatments are likely to target purely the nucleus pulposus (NP), whilst 
mid degeneration where annular tears are present biphasic regeneration of the NP 
and annulus fibrosus (AF) are likely to be required and severe stages where the 
cartilaginous end plate (CEP) is compromised may require a full disc replacement.  
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